Annex 3. IAC may enforce the provisions of Annex 3, so long as IAC remains a shareholder of eLong.
Annex 3. Addendum to the communication concerning a type of retrofit emission control device (REC) pursuant to Regulation No. 132
Annex 3. Example of an arrangement of the approval xxxx a = 8 mm minimum The mechanical coupling device or component or vehicle bearing the approval xxxx shown above is a device or component approved in the Netherlands (E 4), under approval number 2439, meeting the requirements of the 01 series of amendments to this Regulation.
Annex 3. If the Patents marked with either a B1 or B2 restriction are [**] prevails in the [**] and [**] for such Patents broadly cover [**], the licenses under such Patents are limited to discover, develop, make, have made, use, sell, have sold, offer to sell, import and have imported Antisense Products and to practice Antisense Technology; provided that the license will only extend to the issued claims corresponding to the [**] and shall not extend to any other claim of such Patents. The licenses under the Patents marked with an F restriction are limited (i) to discover, develop, make, have made, use, sell, have sold, offer to sell, import and have imported Antisense Products which contain modifications which have [**], (ii) to practice Antisense Technology using oligonucleotides [**] in such oligonucleotides, and (iii) to discover, develop, make, have made, use, sell, have sold, offer to sell, import and have imported Antisense Products which target genes involved in [**]. The licenses under the Patents marked with a C or D restriction are limited to discover, develop, make, have made, use, sell, have sold, offer to sell, import and have imported Antisense Products and practice Antisense Technology, provided that neither such Antisense Products nor such Antisense Technology use, or are used with, [**]. The licenses under the Patents marked with an A restriction are limited to discover, develop, make, have made, use, sell, have sold, offer to sell, import and have imported Antisense Products and practice Antisense Technology, provided that such Antisense Products and Antisense Technology use, or are used with, the technology covered by the claims of such Patents solely for the [**] purposes only. The licenses under the Patents marked with an M restriction are limited to discover, develop, make, have made, use, sell, have sold, offer to sell, import and have imported Antisense Products and practice Antisense Technology, which Antisense Products and Antisense Technology primarily act [**]. The licenses under the Patents marked with a K restriction are limited to discover, develop, make, have made, use, sell, have sold, offer to sell, import and have imported Antisense Products and practice Antisense Technology; provided, however, that such licenses will not extend to [**]. For purposes of this description:
Annex 3. Arrangements of approval marks 1. Arrangement in the approval mark for a seat 80 - 02 2439 a E 4 a 3 a 2 a 3 80 - 02 2439 a = 8 mm min The above approval mark affixed to a seat shows that the seat type concerned has, with regard to the strength of the seats, the test being carried out in accordance with paragraph 2. of Annex 4, been approved in the Netherlands (E4) under number 022439. The approval number indicates that the approval was granted in accordance with the requirements of Regulation No. 80 as amended by the 02 series of amendments.
Annex 3. Arrangements of approval marks 1. Arrangement in the approval mark for a seat a = 8 mm min 80 - 02 2439 a E4
Annex 3. What is behind the “ethics by design” requirement?
Annex 3. (A) contains the balance sheet of CaixaBank, and Annex 3.(B) the balance sheet of Banca Cívica. The balance sheets of CaixaBank and Banca Cívica, checked by their respective external auditors, will be submitted to the approval of the Annual General Meeting of Shareholders of CaixaBank, scheduled for 19 April 2012, and the Annual General Meeting of Shareholders of Banca Cívica, scheduled for 23 May 2012.
Annex 3. 04.1 includes a complete and detailed picture of EFT Estimated Working Capital corresponding to 2016. The sum of the following accounts: (i) Target Financial Debt and (ii) Target Debt Equivalents will be the financial debt of the transaction (“Target Financial Debt of the Transaction”).
Annex 3. 04.1(ii) includes an example of calculating the daily Financial Debt as of the Closing Date.
